Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which completed Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montréal, Canada.

Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals ( ($MIST) ) just unveiled an update. On September 3, 2026, Milestone Pharmaceuticals announced that China’s National Medi...

Milestone Wins China Approval for Etripamil Nasal Spray

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Milestone Pharmaceuticals (MIST) and Labcorp Holding...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MIST	$1.20	-0.83%	1.59M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MIST	$1.20	-0.8%	1.59M
3
4
5
6

MIST

Get Milestone Pharmaceuticals Inc. Data in Excel

Get Milestone Pharmaceuticals Inc. Data in Excel